PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Drug: Treatment D
Drug: Treatment E
Drug: Treatment F
Drug: Treatment G
Drug: Treatment H

First Posted Date: 2019-06-06

Last Posted Date: 2019-11-15

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT03978143

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2019-06-05

Last Posted Date: 2023-06-09

Lead Sponsor: Pfizer

Target Recruit Count: 479

Registration Number: NCT03975790

Locations: 🇺🇸
Pfizer, New York, New York, United States

Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Other: Placebo
Biological: PF-06946860

First Posted Date: 2019-06-05

Last Posted Date: 2020-01-29

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT03974776

Locations: 🇺🇸
Anaheim Clinical Trials LLC-Clinical Research, Anaheim, California, United States

A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Non-alcoholic Steatohepatitis

Interventions: Drug: PF-06835919
Drug: Placebo

First Posted Date: 2019-05-31

Last Posted Date: 2022-05-11

Lead Sponsor: Pfizer

Target Recruit Count: 164

Registration Number: NCT03969719

Locations: 🇨🇦
The Western Centre for Functional and Metabolic Mapping, London, Ontario, Canada
🇺🇸
Hope Clinical Research, Canoga Park, California, United States
🇺🇸
eStudySite, La Mesa, California, United States

and more 101 locations

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

Phase 2

Completed

Conditions: Lyme Borreliosis

Interventions: Biological: VLA15
Biological: Placebo

First Posted Date: 2019-05-31

Last Posted Date: 2023-04-21

Lead Sponsor: Pfizer

Target Recruit Count: 246

Registration Number: NCT03970733

Locations: 🇺🇸
Clinical Research Consulting, LLC, Milford, Connecticut, United States
🇺🇸
Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸
United Medical Associates, Binghamton, New York, United States

and more 2 locations

Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2019-05-28

Last Posted Date: 2021-06-02

Lead Sponsor: Pfizer

Target Recruit Count: 7308

Registration Number: NCT03964649

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

Phase 2

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: PF-06700841
Other: Placebo

First Posted Date: 2019-05-24

Last Posted Date: 2021-08-04

Lead Sponsor: Pfizer

Target Recruit Count: 219

Registration Number: NCT03963401

Locations: 🇵🇱
RCMed Oddzial Sochaczew, Sochaczew, Poland
🇵🇱
Zespol Poradni Specjalistycznych "REUMED" Filia nr 2, Lublin, Poland
🇦🇺
Emeritus Research, Melbourne, Victoria, Australia

and more 45 locations

Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants

Phase 1

Completed

Conditions: Adult
Drug Interactions
Healthy Volunteers
Humans

Interventions: Drug: Lorlatinib 100 mg
Drug: Lorlatinib 50 mg
Drug: Lorlatinib 75 mg

First Posted Date: 2019-05-23

Last Posted Date: 2020-01-18

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT03961997

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Be-bru, Belgium

Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Crisaborole ointment 2%
Drug: Vehicle

First Posted Date: 2019-05-17

Last Posted Date: 2020-07-14

Lead Sponsor: Pfizer

Target Recruit Count: 81

Registration Number: NCT03954158

Locations: 🇯🇵
Fukuwa Clinic, Chuo-ku, Tokyo, Japan
🇯🇵
Sekino Hospital, Toshima-ku, Tokyo, Japan
🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

Phase 3

Active, not recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Etrasimod

First Posted Date: 2019-05-15

Last Posted Date: 2024-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 778

Registration Number: NCT03950232

Locations: 🇧🇪
AZ Delta Roeselare VZW Campus, Roeselare, Belgium
🇫🇷
CHU Nantes - Hôtel Dieu, Nantes, France
🇩🇪
Krankenhaus Waldfriede e.V.,, Berlin, Germany

and more 666 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy